Corporate Overview

Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Our lead program, CYT-0851, is a novel, oral small molecule inhibitor of RAD-51 mediated homologous recombination.

Read more

Latest News

View all news

Latest Presentation

Latest Events

View All Events